Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases

20 Mar 2020

Abstract excerpt

Even though anti-TNF therapy significantly improves the rates of remission in inflammatory bowel disease (IBD) patients, there is a noticeable subgroup of patients who do not respond to treatment. Dysbiosis emerges as a key factor in IBD pathogenesis. The aim of the present study is to profile changes in the gut microbiome and transcriptome before and after administration of the anti-TNF agent Infliximab (IFX)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Gut microbiota and health
Share to Inflammatory Bowel Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32244928
DOI: 10.3390/microorganisms8030438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel DiseasesPMID 32244928Read ↗

Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease.Semantic proximity Read ↗

Mucosal host–microbe interactions associate with clinical phenotypes in inflammatory bowel diseaseSemantic proximity Read ↗

Functional Impacts of the Intestinal Microbiome in the Pathogenesis of Inflammatory Bowel DiseaseSemantic proximity Read ↗

Dynamic Changes in the Gut Microbiota Composition during Adalimumab Therapy in Patients with Ulcerative Colitis: Implications for Treatment Response Prediction and Therapeutic TargetsSemantic proximity Read ↗

Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn's Disease and Ulcerative Colitis-An International Meta-Analysis.Semantic proximity Read ↗

Gut microbiome–based therapeutics in inflammatory bowel diseaseSemantic proximity Read ↗

Microbiome-Based Biomarkers for IBDSemantic proximity Read ↗

A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist?Semantic proximity Read ↗

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseasesSemantic proximity Read ↗

Microbial imbalance in inflammatory bowel disease patients at different taxonomic levelsSemantic proximity Read ↗

Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).Semantic proximity Read ↗

Dynamics of metatranscription in the inflammatory bowel disease gut microbiome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.